IBio Competitors
| IBIO Stock | USD 2.10 0.05 2.33% |
IBio Common vs Boundless Bio Correlation
Modest diversification
The correlation between iBio Common Stock and BOLD is 0.2 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding iBio Common Stock and BOLD in the same portfolio, assuming nothing else is changed.
Moving against IBio Stock
| 0.64 | ACLX | Arcellx | PairCorr |
| 0.59 | CRBP | Corbus Pharmaceuticals | PairCorr |
| 0.54 | RANI | Rani Therapeutics | PairCorr |
| 0.52 | BCT | Briacell Therapeutics | PairCorr |
| 0.5 | MBIO | Mustang Bio | PairCorr |
IBio Common Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between IBio Common and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of IBio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of iBio Common Stock does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between IBio Stock performing well and IBio Common Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze IBio Common's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ITRM | 4.41 | (1.08) | 0.00 | (0.49) | 0.00 | 9.38 | 28.58 | |||
| PLUR | 3.77 | (0.10) | 0.00 | (0.03) | 0.00 | 9.30 | 31.25 | |||
| INTS | 13.68 | 4.63 | 0.41 | (31.00) | 8.40 | 12.20 | 433.59 | |||
| RLYB | 3.05 | 0.06 | 0.02 | 0.08 | 3.04 | 8.33 | 21.25 | |||
| XCUR | 5.84 | 0.30 | 0.02 | (0.18) | 8.49 | 21.22 | 63.80 | |||
| KLTO | 4.51 | (1.03) | 0.00 | (0.27) | 0.00 | 10.34 | 28.13 | |||
| ANTX | 2.61 | (0.22) | 0.00 | (0.33) | 0.00 | 4.55 | 32.31 | |||
| CVKD | 4.65 | (0.77) | 0.00 | (0.38) | 0.00 | 8.11 | 58.15 | |||
| PSTV | 4.84 | (1.26) | 0.00 | (0.48) | 0.00 | 8.93 | 48.30 | |||
| BOLD | 2.07 | (0.36) | 0.00 | (0.81) | 0.00 | 4.13 | 16.75 |
Cross Equities Net Income Analysis
Compare iBio Common Stock and related stocks such as Iterum Therapeutics PLC, Pluri Inc, and Intensity Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (38.4 M) | (24.8 M) | (28.5 M) | (29.9 M) |
| PLUR | (77.9 K) | (14.8 M) | (21.2 M) | (26.9 M) | (24.7 M) | (23.2 M) | (27.8 M) | (26.1 M) | (35.3 M) | (29.2 M) | (49.9 M) | (41.2 M) | (28.3 M) | (20.9 M) | (22.6 M) | (20.3 M) | (21.3 M) |
| INTS | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (6 M) | (7.9 M) | (7.6 M) | (10.5 M) | (16.3 M) | (14.6 M) | (13.9 M) |
| RLYB | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (17.6 M) | (26.4 M) | (47 M) | (66.7 M) | (74.6 M) | (57.8 M) | (52 M) | (54.6 M) |
| XCUR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (16.9 M) | (11 M) | (22.4 M) | (26.3 M) | (24.7 M) | (64.1 M) | (2.6 M) | (16.9 M) | (9.7 M) | (8.7 M) | (9.2 M) |
| KLTO | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (1.1 M) | (598.6 K) | (707.5 K) | (6.2 M) | (5.5 M) | (5.3 M) |
| ANTX | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| CVKD | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (8.4 M) | (10.7 M) | (9.6 M) | (10.1 M) |
| PSTV | (2.1 M) | (32.5 M) | (32.3 M) | (26.2 M) | (37.4 M) | (18.7 M) | (22 M) | (22.7 M) | (12.6 M) | (10.9 M) | (8.2 M) | (13.4 M) | (20.3 M) | (13.3 M) | (13 M) | (11.7 M) | (12.3 M) |
| BOLD | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (90.2 M) | (128.8 M) | (25.2 M) | (25.2 M) | (25.2 M) | (45.9 M) | (49.4 M) | (65.4 M) | (75.2 M) | (78.9 M) |
iBio Common Stock and related stocks such as Iterum Therapeutics PLC, Pluri Inc, and Intensity Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in iBio Common Stock financial statement analysis. It represents the amount of money remaining after all of iBio Common Stock operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.IBio Common Competitive Analysis
The better you understand IBio Common competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, IBio Common's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across IBio Common's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
IBio Common Competition Performance Charts
Five steps to successful analysis of IBio Common Competition
IBio Common's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by iBio Common Stock in relation to its competition. IBio Common's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of IBio Common in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact IBio Common's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to iBio Common Stock, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your IBio Common position
In addition to having IBio Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Services Thematic Idea Now
Communication Services
Companies that provide networking, telecom, and long distance services. The Communication Services theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out IBio Common Correlation with its peers. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Will Biotechnology sector continue expanding? Could IBio diversify its offerings? Factors like these will boost the valuation of IBio Common. Market participants price IBio higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every IBio Common data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.40) | Revenue Per Share | Quarterly Revenue Growth 0.143 | Return On Assets | Return On Equity |
iBio Common Stock's market price often diverges from its book value, the accounting figure shown on IBio's balance sheet. Smart investors calculate IBio Common's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since IBio Common's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between IBio Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.